MCID: PPT001
MIFTS: 51

Peptic Esophagitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Esophagitis

MalaCards integrated aliases for Peptic Esophagitis:

Name: Peptic Esophagitis 12 15 17 70
Reflux Esophagitis 12 73 15
Gastro-Esophageal Reflux Disease with Esophagitis 70
Peptic Reflux Disease 12
Reflux Oesophagitis 12
Esophagitis, Peptic 44

Classifications:



External Ids:

Disease Ontology 12 DOID:13976
ICD9CM 34 530.11
MeSH 44 D004942
SNOMED-CT 67 57643001
UMLS 70 C0014869 C0677659

Summaries for Peptic Esophagitis

MalaCards based summary : Peptic Esophagitis, also known as reflux esophagitis, is related to gastroparesis and esophagitis, eosinophilic, 1. An important gene associated with Peptic Esophagitis is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Human cytomegalovirus infection and Toll-Like receptor Signaling Pathways. The drugs Trimebutine and Zinc have been mentioned in the context of this disorder. Affiliated tissues include colon, smooth muscle and lymph node, and related phenotypes are digestive/alimentary and neoplasm

Wikipedia : 73 Gastroesophageal reflux disease (GERD), is a chronic condition in which stomach contents rise up into... more...

Related Diseases for Peptic Esophagitis

Diseases related to Peptic Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 705)
# Related Disease Score Top Affiliating Genes
1 gastroparesis 31.9 MLN HRH2 GAST
2 esophagitis, eosinophilic, 1 30.9 CCL26 ATP4A ATP12A
3 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.7 S100A8 PTGS2 HRH2 GAST
4 duodenogastric reflux 30.6 MLN GAST ATP4A ATP12A
5 gastrojejunal ulcer 30.5 PTGS2 ATP4A ATP12A
6 gastric dilatation 30.5 ATP4A ATP12A
7 cascade stomach 30.4 HRH2 ATP4A ATP12A
8 superior mesenteric artery syndrome 30.4 HRH2 ATP4A ATP12A
9 pernicious anemia 30.3 GAST ATP4A ATP12A
10 esophageal varix 30.3 ATP4A ATP12A ALB
11 microinvasive gastric cancer 30.2 S100A8 GAST CDX2 ATP4A ATP12A
12 postcholecystectomy syndrome 30.2 MLN GAST
13 hernia, hiatus 30.2 MLN LCT LAT2 HRH2 GAST CYP2C19
14 postgastrectomy syndrome 30.2 MLN GAST ATP12A
15 zollinger-ellison syndrome 30.1 MLN HRH2 GAST ATP4A ATP12A
16 gastroduodenitis 30.0 GAST CCL26 ATP4A ATP12A
17 esophageal candidiasis 30.0 CYP2C19 CCL26 ATP4A ATP12A
18 esophagitis 29.9 TNF PTGS2 IL6 IL1B HRH2 GAST
19 ascaris lumbricoides infection 29.9 IL6 IL1B CXCL8
20 esophagus adenocarcinoma 29.8 PTGS2 CDX2 ATP4A ATP12A
21 helicobacter pylori infection 29.8 TNF IL1B CYP2C19 CXCL8
22 duodenum disease 29.8 S100A8 GAST CDX2 ATP4A ATP12A
23 volvulus of midgut 29.8 MLN ATP4A ATP12A ALB
24 autonomic neuropathy 29.7 MLN GAST ALB
25 dyskinesia of esophagus 29.7 MLN HRH2 CCL26 ATP4A ATP12A
26 bronchiectasis 29.7 TNF IL6 IL1B CXCL8
27 varicose veins 29.7 TNF IL6 CXCL8
28 gastric adenocarcinoma 29.7 S100A8 PTGS2 GAST CDX2
29 fatty liver disease 29.6 TNF IL6 IL1B CXCL8
30 esophageal disease 29.6 CCL26 ATP4A ATP12A ALB
31 acute pancreatitis 29.5 TNF IL6 IL1B CXCL8
32 hepatitis a 29.5 TNF IL1B ALB
33 systemic scleroderma 29.5 TNF MLN IL6 HRH2 GAST
34 candidiasis 29.5 TNF IL6 IL1B CXCL8
35 tropical sprue 29.5 LCT GAST ATP4A ATP12A ALB
36 dermatitis 29.5 TNF IL6 IL1B CXCL8
37 irritable bowel syndrome 29.5 TNF MLN IL6 IL1B CXCL8
38 tonsillitis 29.5 TNF IL6 IL1B CXCL8
39 laryngitis 29.4 TNF IL6 IL1B HRH2 ATP4A ATP12A
40 food allergy 29.4 TNF CXCL8 ALB
41 allergic disease 29.4 TNF IL6 IL1B CXCL8
42 barrett esophagus 29.4 S100A8 PTGS2 GAST CDX2 ATP4A ATP12A
43 portal hypertension 29.4 TNF CXCL8 ALB
44 glossitis 29.4 TNF IL6 IL1B ATP4A ATP12A
45 anxiety 29.4 TNF IL6 IL1B CYP2C19
46 cystitis 29.3 TNF PTGS2 IL6 CXCL8
47 pharyngitis 29.3 TNF PTGS2 IL6 IL1B CXCL8
48 periodontitis 29.3 TNF PTGS2 IL6 IL1B CXCL8
49 atrophic gastritis 29.3 TNF S100A8 PTGS2 IL6 IL1B GAST
50 pulmonary disease, chronic obstructive 29.2 TNF IL6 IL1B CXCL8 ALB

Comorbidity relations with Peptic Esophagitis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Bronchitis
Deficiency Anemia Esophageal Disease
Esophagitis Gastroesophageal Reflux
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Peptic Esophagitis:



Diseases related to Peptic Esophagitis

Symptoms & Phenotypes for Peptic Esophagitis

MGI Mouse Phenotypes related to Peptic Esophagitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.61 ALB ATP12A ATP4A CDX2 GAST HRH2
2 neoplasm MP:0002006 9.23 ALB ATP4A CDX2 GAST IL1B IL6

Drugs & Therapeutics for Peptic Esophagitis

Drugs for Peptic Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimebutine Approved Phase 4 39133-31-8
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
5
Rebamipide Approved, Investigational Phase 4 90098-04-7
6
Calcium polycarbophil Approved Phase 4 126040-58-2
7
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
8
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Maleic acid Experimental Phase 4 110-16-7 444266
11
Polaprezinc Experimental Phase 4 107667-60-7
12
Mosapride Investigational Phase 4 112885-41-3
13
Indobufen Investigational Phase 4 63610-08-2
14 Parasympatholytics Phase 4
15 Antioxidants Phase 4
16 Serotonin Receptor Agonists Phase 4
17 Cathartics Phase 4
18 Psyllium Phase 4
19 Laxatives Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Fibrinolytic Agents Phase 4
22 Antirheumatic Agents Phase 4
23 Cyclooxygenase Inhibitors Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Analgesics Phase 4
26 Platelet Aggregation Inhibitors Phase 4
27 Antipyretics Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
30
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
31
Famotidine Approved Phase 3 76824-35-6 3325
32
Sodium citrate Approved, Investigational Phase 3 68-04-2
33
Ranitidine Approved, Withdrawn Phase 3 66357-35-5, 66357-59-3, 82530-72-1 3001055
34
Tegaserod Approved, Investigational, Withdrawn Phase 3 189188-57-6, 145158-71-0 122724
35
tannic acid Approved Phase 3 1401-55-4
36
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
37
Nizatidine Approved Phase 3 76963-41-2 3033637
38
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
39
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
40
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
41
Lafutidine Investigational Phase 3 118288-08-7 5282136
42 Histamine H2 Antagonists Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44 Histamine Antagonists Phase 3
45 Ranitidine bismuth citrate Phase 3
46 Citrate Phase 3
47
Bismuth Phase 3 7440-69-9 16682734 105143
48 Bismuth tripotassium dicitrate Phase 3
49 Omeprazole, sodium bicarbonate drug combination Phase 3
50 Anti-Asthmatic Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 283)
# Name Status NCT ID Phase Drugs
1 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
2 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
3 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
4 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
5 Efficacy of Zinc L-carnosine (Hepilor®) in Maintaining Remission of Gastroesophageal Reflux Disease: a Randomised, Double-blind, Placebo-controlled Study Unknown status NCT03467438 Phase 4 Zinc-l-carnosine
6 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
7 An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
8 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE) Completed NCT03116841 Phase 4 Vonoprazan
9 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
10 Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
11 Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
12 Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
13 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
14 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
15 Evaluation of Smectite Effect As A Food Thickener On Gastroesophageal Reflux Disease In Neonates Using Combined Esophageal Multichannel Intraluminal Impedance Completed NCT04788485 Phase 4 Diosmectite
16 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
17 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
18 Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing Completed NCT00307944 Phase 4 Pantoprazole
19 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
20 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
21 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
22 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
23 PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD Completed NCT00261339 Phase 4 Pantoprazole
24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
25 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
26 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
27 Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial Completed NCT02907632 Phase 4 Metoclopramide;Placebo
28 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
29 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
30 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
31 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
33 Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Control Clinical Trials Not yet recruiting NCT04129008 Phase 4 Indobufen and aspirin mimetic;Aspirin and indobufen mimetic
34 The Effect of Dexilant Treatment on Esophageal Hypersensitivity in GERD Related Non Cardiac Chest Pain Patients Withdrawn NCT01637571 Phase 4 Dexilant;Dexilant Placebo
35 A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients Unknown status NCT00480285 Phase 3
36 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - Completed NCT00229424 Phase 3 Lafutidine;Famotidine
37 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis Completed NCT00770913 Phase 2, Phase 3 E3810;E3810;E3810
38 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
39 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of D961H 20 mg Twice Daily Oral Administration and D961H 20 mg Once Daily Oral Administration in Patients With Refractory Reflux Esophagitis Completed NCT01669811 Phase 3 Esomeprazole (D961H) twice daily;Esomeprazole (D961H) once daily
40 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
41 Omeprazole Versus Anti-reflux Surgery in the Long-term Management of Peptic Esophagitis - a 10 Year Follow up Study of Patients Previously Studied for 5 Years - A Nordic Multicentre Study Completed NCT00256737 Phase 3 Omeprazole
42 A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis. Completed NCT00321737 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Placebo
43 Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). Completed NCT00171418 Phase 3 Tegaserod
44 A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease Completed NCT00165672 Phase 3 RABEPRAZOLE SODIUM;RABEPRAZOLE SODIUM
45 Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy Completed NCT00164840 Phase 3 Esomeprazole
46 Complete Remission: Evaluation of the Complete Remission Rates in Patients With Symptomatic Non-erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (GERD) Treated With Pantoprazole 40 Milligram o.d. Over 4 or 8 or 12 Weeks Completed NCT00163306 Phase 3 Pantoprazole
47 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors Completed NCT03561883 Phase 3 IW-3718;placebo
48 A Phase 3, Randomized, Double Blind, Placebo Control, Multicenter Study to Evaluate the Efficacy and Safety of TAK- 438 (10 and 20 mg Once-Daily) in Patients With Non-Erosive Gastroesophageal Reflux Disease. Completed NCT01474369 Phase 3 TAK-438;TAK-438;Placebo
49 A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis Completed NCT00255164 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Placebo
50 A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis Completed NCT00255151 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Placebo

Search NIH Clinical Center for Peptic Esophagitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Calcium Glycerophosphate
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Famotidine
Magnesium Hydroxide
MILK OF MAGNESIA
Nizatidine

Cochrane evidence based reviews: esophagitis, peptic

Genetic Tests for Peptic Esophagitis

Anatomical Context for Peptic Esophagitis

MalaCards organs/tissues related to Peptic Esophagitis:

40
Colon, Smooth Muscle, Lymph Node, Small Intestine, Tongue, Pancreas, Endothelial

Publications for Peptic Esophagitis

Articles related to Peptic Esophagitis:

(show top 50) (show all 3717)
# Title Authors PMID Year
1
Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor non-responders compared with proton pump inhibitor responders of eosinophilic esophagitis. 61
32909083 2021
2
A novel method for π-shaped esophagojejunostomy and double-tract reconstruction (DTR) as an alternative in totally laparoscopic or robotic proximal gastrectomy for treating upper third proximal early gastric cancer. 61
33576931 2021
3
Key molecules involved in the Th17/Treg balance are associated with the pathogenesis of reflux esophagitis and Barrett's esophagus. 61
32920737 2021
4
Experience with Esophageal Granular Cell Tumors: Clinical and Endoscopic Analysis of 22 Cases. 61
32474763 2021
5
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancer. 61
33118118 2021
6
Effect of Esophagus-Remnant Stomach Anterior Wall Anastomosis on Postoperative Reflux and Nutritional Status in Patients with Early- and Intermediate-Stage Proximal Gastric Cancer. 61
33666512 2021
7
Sudden Appearance of Widespread Esophageal Squamous Papilloma With Reflux Esophagitis. 61
32036041 2021
8
Feasibility and quality of life assessment of laparoscopic proximal gastrectomy using double-tract reconstruction. 61
33452650 2021
9
Study on the relationship of depression, anxiety, lifestyle and eating habits with the severity of reflux esophagitis. 61
33743601 2021
10
[Long-term consequences of esophageal atresia; esophageal and lung abnormalities in adulthood]. 61
33720564 2021
11
Clinical outcomes of gastric tube reconstruction following laparoscopic proximal gastrectomy for early gastric cancer in the upper third of the stomach: experience with 100 consecutive cases. 61
33611694 2021
12
[Safety and feasibility of laparoscopic double-flap technique in digestive tract reconstruction after proximal gastrectomy for esophagogastric junction tumors larger than 5 cm]. 61
33508923 2021
13
The Impact of Erosive Reflux Esophagitis on the Decline of Lung Function in the General Population. 61
33527781 2021
14
Efficacy of vonoprazan for refractory reflux esophagitis after esophagectomy. 61
33567428 2021
15
Stimulated saliva secretion is reduced in proton pump inhibitor-resistant severe reflux esophagitis patients. 61
33590389 2021
16
Extra-esophageal symptoms in individuals with and without erosive esophagitis: a case-control study in Albania. 61
33593300 2021
17
The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis. 61
32863366 2021
18
Daidzein ameliorates experimental acute reflux esophagitis in rats via regulation of cytokines. 61
33714284 2021
19
Comparative analysis of laparoscopic proximal gastrectomy plus semi-embedded valve anastomosis with laparoscopic total gastrectomy for adenocarcinoma of the esophagogastric junction: a single-center retrospective cohort study. 61
33588854 2021
20
Functional Outcomes of Delta-Shaped Anastomosis After Laparoscopic Distal Gastrectomy. 61
32026335 2021
21
Severe Upper Gastrointestinal Hemorrhage Caused by Reflux Esophagitis. 61
33590404 2021
22
Esophagitis in Cats and Dogs. 61
33187619 2021
23
Clinical outcomes of proximal gastrectomy for gastric cancer: A comparison between the double-flap technique and jejunal interposition. 61
33626086 2021
24
Comparison of 5-year postoperative outcomes after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: Results from a multi-institutional randomized controlled trial. 61
33532685 2021
25
The Spectrum of Helicobacter-Mediated Diseases. 61
33197219 2021
26
Time trends of causes of upper gastrointestinal bleeding and endoscopic findings. 61
33078720 2021
27
Treatment strategy for laparoscopic hiatal hernia repair. 61
33472278 2021
28
Peroral endoscopic myotomy for patients with achalasia with previous Heller myotomy: a systematic review and meta-analysis. 61
32522483 2021
29
Inhibitory effects of Camellia japonica on cell inflammation and acute rat reflux esophagitis. 61
33413538 2021
30
Protective Effects of Inflammation of Curcumae Longae Rhizoma 30% EtOH Extract on Acute Reflux Esophagitis Rats. 61
33532497 2021
31
Factors affecting the treatment outcomes of laparoscopic fundoplication for erosive reflux esophagitis: findings of esophageal pathological function tests. 61
33491102 2021
32
Clinical features and therapeutic responses to proton pump inhibitor in patients with severe reflux esophagitis: A multicenter prospective observational study. 61
33490619 2021
33
Relationship between gastroesophageal reflux disease (GERD) and constipation: laxative use is common in GERD patients. 61
32860581 2021
34
Development and Validation of an Automatic Image-Recognition Endoscopic Report Generation System: A Multicenter Study. 61
33395075 2020
35
[Comparison of different reconstruction procedures after distal gastrectomy in patients with gastric cancer]. 61
33371636 2020
36
Inverse time trends of peptic ulcer and reflux esophagitis show significant association with reduced prevalence of Helicobacter pylori infection. 61
32536216 2020
37
Size-dependent differences in the proximal remnant stomach: how much does a small remnant stomach after subtotal gastrectomy work? 61
31950274 2020
38
Double Tract Reconstruction Reduces Reflux Esophagitis and Improves Quality of Life After Radical Proximal Gastrectomy for Patients with Upper Gastric or Esophagogastric Adenocarcinoma. 61
33421979 2020
39
Effects of Chaihu-Shugan-San for reflux esophagitis: A protocol for systematic review and meta-analysis. 61
33285744 2020
40
Esophageal symptoms versus epigastric symptoms: Relevance for diagnosis of gastroesophageal reflux disease. 61
32975045 2020
41
CD8 T-Cell-Predominant Lymphocytic Esophagitis is One of the Major Patterns of Lymphocytic Inflammation in Gastroesophageal Reflux Disease. 61
33373450 2020
42
Chronic atrophic gastritis and Helicobacter pylori infection status in liver transplant recipients. 61
33207018 2020
43
[Efficacy and safety of pylorus-preserving gastrectomy for early gastric cancer located in the middle third of the stomach: a meta-analysis]. 61
33212558 2020
44
Trends in gastroesophageal reflux disease in Japanese children and adolescents. 61
32473087 2020
45
The Usefulness of the Measurement of Esophagogastric Junction Distensibility by EndoFLIP in the Diagnosis of Gastroesophageal Reflux Disease. 61
33115968 2020
46
Relationship Between Gastroesophageal Reflux Disease and Endoscopic Finding "Iodine-Unstained Streak". 61
33224371 2020
47
Proximal gastrectomy with anti-reflux anastomosis for patients with adenocarcinoma of the esophagogastric junction: The simple and safe triangle-valve technique. 61
32963781 2020
48
Clinical outcomes of laparoscopic and endoscopic cooperative surgery for submucosal tumors on the esophagogastric junction: a retrospective single-center analysis. 61
32476110 2020
49
Helicobacter pylori Infection and Serum Pepsinogen Level With the Risk of Gastric Precancerous Conditions: A Cross-sectional Study of High-risk Gastric Cancer Population in China. 61
33116065 2020
50
Urinary exposure of N-nitrosamines and associated risk of esophageal cancer in a high incidence area in China. 61
32526409 2020

Variations for Peptic Esophagitis

Expression for Peptic Esophagitis

Search GEO for disease gene expression data for Peptic Esophagitis.

Pathways for Peptic Esophagitis

Pathways related to Peptic Esophagitis according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 TNF PTGS2 IL6 IL1B CXCL8
2
Show member pathways
12.68 TNF PTGS2 IL6 IL1B CXCL8
3
Show member pathways
12.29 TNF IL6 CXCL8 CCL26
4
Show member pathways
12.25 TNF PTGS2 IL6 IL1B CXCL8
5
Show member pathways
12.25 TNF PTGS2 IL6 IL1B ALB
6 12.21 TNF IL6 IL1B CXCL8
7
Show member pathways
12.18 TNF PTGS2 IL6 IL1B
8
Show member pathways
12.15 TNF IL6 IL1B CXCL8
9 12.14 TNF IL6 IL1B CXCL8
10
Show member pathways
12.07 TNF S100A8 PTGS2 IL6 IL1B CXCL8
11 12.05 TNF IL6 IL1B CXCL8
12 11.93 TNF PTGS2 IL6 IL1B
13 11.89 TNF PTGS2 IL1B CXCL8
14 11.88 TNF IL6 IL1B CXCL8
15 11.88 TNF PTGS2 IL6 IL1B CXCL8
16 11.85 TNF IL6 IL1B
17 11.85 TNF IL6 IL1B CXCL8
18 11.82 TNF PTGS2 IL6 IL1B CXCL8
19 11.81 TNF IL6 IL1B CXCL8
20
Show member pathways
11.72 TNF IL6 IL1B
21
Show member pathways
11.72 TNF PTGS2 CXCL8
22 11.7 TNF IL6 IL1B
23 11.69 TNF IL6 IL1B CXCL8
24 11.6 TNF IL6 IL1B CXCL8
25 11.53 PTGS2 IL6 CXCL8
26 11.53 TNF IL6 IL1B CXCL8
27 11.46 TNF IL6 IL1B CXCL8
28 11.39 TNF IL6 IL1B CDX2
29 11.37 TNF IL6 IL1B
30 11.33 TNF IL6 IL1B
31 11.29 TNF IL6 IL1B
32 11.27 TNF IL6 IL1B
33 11.23 TNF IL6 IL1B
34
Show member pathways
11.15 TNF PTGS2 IL6 IL1B CXCL8
35 10.97 TNF IL6 IL1B CXCL8 CCL26
36 10.75 IL6 IL1B
37 10.74 TNF PTGS2 IL6 CXCL8
38 10.71 TNF PTGS2 IL6 IL1B CXCL8
39 10.2 HRH2 GAST ATP4A

GO Terms for Peptic Esophagitis

Cellular components related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF S100A8 MLN IL6 IL1B GAST
2 extracellular space GO:0005615 9.28 TNF S100A8 IL6 IL1B GAST CXCL8

Biological processes related to Peptic Esophagitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.85 TNF PTGS2 IL6 IL1B CXCL8
2 immune response GO:0006955 9.85 TNF IL6 IL1B HRH2 CXCL8 CCL26
3 cellular response to lipopolysaccharide GO:0071222 9.84 TNF IL6 IL1B CXCL8
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 TNF S100A8 IL6 IL1B
5 positive regulation of inflammatory response GO:0050729 9.81 TNF S100A8 IL1B
6 regulation of inflammatory response GO:0050727 9.8 TNF S100A8 PTGS2
7 positive regulation of interleukin-6 production GO:0032755 9.8 TNF IL6 IL1B
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 TNF PTGS2 IL6
9 neutrophil chemotaxis GO:0030593 9.77 S100A8 CXCL8 CCL26
10 regulation of insulin secretion GO:0050796 9.76 TNF IL6 IL1B
11 response to glucocorticoid GO:0051384 9.75 TNF PTGS2 IL6
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 TNF PTGS2 IL6
13 positive regulation of interleukin-8 production GO:0032757 9.72 TNF IL6 IL1B
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 TNF PTGS2 IL1B
15 sodium ion export across plasma membrane GO:0036376 9.65 ATP4A ATP12A
16 cellular potassium ion homeostasis GO:0030007 9.64 ATP4A ATP12A
17 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.64 ATP4A ATP12A
18 regulation of neuroinflammatory response GO:0150077 9.61 PTGS2 IL6
19 regulation of establishment of endothelial barrier GO:1903140 9.61 TNF IL1B
20 positive regulation of vascular endothelial growth factor production GO:0010575 9.61 PTGS2 IL6 IL1B
21 negative regulation of lipid storage GO:0010888 9.59 TNF IL6
22 negative regulation of neurogenesis GO:0050768 9.58 TNF IL6 IL1B
23 positive regulation of prostaglandin biosynthetic process GO:0031394 9.57 PTGS2 IL1B
24 positive regulation of glial cell proliferation GO:0060252 9.5 TNF IL6 IL1B
25 sequestering of triglyceride GO:0030730 9.49 TNF IL1B
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 TNF IL1B
27 positive regulation of neuroinflammatory response GO:0150078 9.43 TNF IL6 IL1B
28 vascular endothelial growth factor production GO:0010573 9.33 TNF IL6 IL1B
29 inflammatory response GO:0006954 9.17 TNF S100A8 PTGS2 IL6 IL1B CXCL8
30 positive regulation of fever generation GO:0031622 9.13 TNF PTGS2 IL1B

Molecular functions related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
2 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
3 cytokine activity GO:0005125 9.02 TNF IL6 IL1B CXCL8 CCL26
4 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A

Sources for Peptic Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....